Thiếu vitamin D như một yếu tố thuận lợi đối với viêm dạ dày thể A teo: Nghiên cứu trường hợp - Đối chứng và Tổng quan tài liệu về tương tác của vitamin D với hệ miễn dịch

Clinical Reviews in Allergy - Tập 42 - Trang 355-364 - 2011
Antonio Antico1, Renato Tozzoli2, Davide Giavarina3, Elio Tonutti4, Nicola Bizzaro5
1Department of Clinical Pathology, Cittadella General Hospital, Cittadella, Italy
2Laboratory of Clinical Chemistry and Microbiology, Beata Vergine delle Grazie Hospital, Latisana, Italy
3Laboratory of Clinical Chemistry and Hematology, Vicenza General Hospital, Vicenza, Italy
4Clinical Immunology and Allergology, Udine University Hospital, Udine, Italy
5Laboratory of Clinical Pathology, S. Antonio Hospital, Tolmezzo, Italy

Tóm tắt

1,25-Dihydroxyvitamin D thể hiện đặc tính điều hòa miễn dịch và chống viêm, và các tế bào tham gia vào phản ứng miễn dịch bẩm sinh và thích nghi đều biểu hiện thụ thể vitamin D và có khả năng sản xuất cũng như phản ứng với hormone này. Bài viết này nhằm mô tả vai trò điều hòa miễn dịch phức tạp của vitamin D và mô tả liệu có mối tương quan giữa viêm dạ dày thể A teo và thiếu vitamin D hay không. Chúng tôi đã nghiên cứu 62 bệnh nhân viêm dạ dày tự miễn (AIG) và so sánh họ với 54 bệnh nhân viêm dạ dày lympho, 21 bệnh nhân viêm dạ dày do Helicobacter pylori và 212 đối tượng khỏe mạnh. Chúng tôi cũng đã phân tích thống kê nồng độ vitamin D trong 36,384 bệnh nhân ngoại trú được giới thiệu đến các phòng khám của chúng tôi. Nồng độ 25-Hydroxyvitamin D, chất chuyển hóa có thể đo được để xác định tình trạng vitamin D trong huyết tương, đã được đo bằng phương pháp hóa phát quang. Mức trung bình của 25-OHD trong nhóm AIG là 9.8 ± 5.6 ng/mL (khoảng tin cậy (CI) 95% 8.4–11.2), 11.1 ± 8.4 (CI 7.5–14.7) trong bệnh nhân viêm dạ dày do H. pylori, 22.2 ± 13.5 (CI 18.6–25.8) trong bệnh nhân viêm dạ dày lympho không đặc hiệu, 21.3 ± 12.2 (CI 19.7–22.9) trong nhóm khỏe mạnh, và 21.8 ± 13.1 (CI 21.7–21.9) trong tổng số 36,384 bệnh nhân ngoại trú. Mức vitamin D ở bệnh nhân AIG thấp hơn đáng kể so với bệnh nhân viêm dạ dày không đặc hiệu hoặc so với quần thể chung, điều này hỗ trợ giả thuyết rằng thiếu vitamin D có thể là một yếu tố nguy cơ cho sự phát triển của các bệnh tự miễn. Nồng độ vitamin D thấp ở bệnh nhân viêm dạ dày do H. pylori có thể đóng vai trò như một yếu tố dễ gây nguy cơ cho sự tấn công mạnh mẽ hơn của tế bào Th1 vào biểu mô dạ dày.

Từ khóa

#vitamin D #viêm dạ dày tự miễn #thiếu vitamin D #hệ miễn dịch #nghiên cứu trường hợp - đối chứng

Tài liệu tham khảo

Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491S–499S Zhang R, Naughton DP (2010) Vitamin D in health and disease: current perspectives. Nutr J 9:65 Cappelletti P, Tozzoli R (2010) Laboratory and hypercalcemia. In: Lumachi F, Basso SMM (eds) Hypercalcemia pathophysiology and treatment. Bentham Science, Sharjah, pp 45–61 Rojas-Rivera J, De La Piedra C, Ramos A et al (2010) The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 25:2850–2865 Hewison M, Zehnder D, Chakraverty R et al (2004) Vitamin D and barrier function: a novel role for extra-renal 1a-hydroxylase. Mol Cell Endocrinol 215:31–38 Bises G, Kallay E, Weiland T et al (2004) 25-Hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 52:985–989 Adorini L, Penna G, Giarratana N et al (2004) Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol 89–90:437–441 Zehnder D, Bland R, Chana RS et al (2002) Synthesis of 1, 25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13:621–629 Eyles DW, Smith S, Kinobe R et al (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29:21–30 Segersten U, Holm PK, Bjorklund P et al (2005) 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1-hydroxylated vitamin D analogue. Breast Cancer Res 7:980–986 Townsend K, Evans KN, Campbell MJ et al (2005) Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 97:103–119 Segersten U, Correa P, Hewison M et al (2002) 25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967–2972 Evans KN, Bulmer JN, Kilby MD et al (2004) Vitamin D and placental–decidual function. J Soc Gynecol Investig 11:263–271 Ma JF, Nonn L, Campbell MJ et al (2004) Mechanisms of decreased vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol 221:67–74 Bikle DD, Chang S, Crumrine D et al (2004) 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol 122:984–992 Griffin MD, Xing N, Kumar R (2003) Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23:117–145 Norman AW, Mizwicki MT, Okamura WH (2003) Ligand structure–function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment). Recent Results Cancer Res 164:55–82 Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116:2062–2072 DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80:1689–1696 Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281 Cooke NE, Haddad JG (1989) Vitamin D binding protein (Gc-globulin). Endocr Rev 10:294–307 Dusso AS, Negrea L, Gunawardhana S et al (1991) On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687–1692 Takemoto F, Shinki T, Yokoyama K et al (2003) Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 64:414–420 Yamane T, Takeuchi K, Yamamoto Y et al (2002) Legumain from bovine kidney: its purification, molecular cloning, immunohistochemical localization and degradation of annexin II and vitamin D-binding protein. Biochim Biophys Acta 1596:108–120 Adams JS, Chen H, Chun RF et al (2003) Novel regulators of vitamin D action and metabolism: lessons learned at the Los Angeles zoo. J Cell Biochem 88:308–314 Nykjaer A, Dragun D, Walther D et al (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96:507–515 Liu W, Yu WR, Carling T et al (1998) Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Investig 28:100–107 Brandi L (2008) 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol—an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull 55:186–210 Brenza HL, Kimmel-Jehan C, Jehan F et al (1998) Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 95:1387–1391 Tsujikawa H, Kurotaki Y, Fujimori T et al (2003) Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17:2393–2403 Dong X, Lutz W, Schroeder TM et al (2005) Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci USA 102:16007–16012 Adorini L, Penna G (2008) Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4:404–412 Norman AW, Mizwicki MT, Norman DPG (2004) Steroid hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3:27–41 Pinette KV, Yee YK, Amegadzie BY et al (2003) Vitamin D receptor as a drug discovery target. Min Rev Med Chem 3:193–204 Brown AJ, Dusso A, Slatopolsky E (1999) Vitamin D. Am J Physiol Renal Physiol 277:F157–F175 Sutton ALM, MacDonald PN (2003) Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol 17:777–791 Strugnell SA, Deluca HF (1997) The vitamin D receptor—structure and transcriptional activation. Proc Soc Exp Biol Med 215:223–228 Kliewer SA, Umesono K, Mangelsdorf DJ et al (1992) Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446–449 Cheskis B, Freedman LP (1994) Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol Cell Biol 14:3329–3338 Dusso AS, Brown AJ (2009) Vitamin D: molecular biology and gene regulation. In: Singh AJ, Williams GH (eds) Textbook of nephro-endocrinology. Elsevier, San Diego, pp 69–93 Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662–687 Oñate SA, Tsai SY, Tsai MJ et al (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357 Chen HW, Lin RJ, Schiltz RL et al (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580 Rachez C, Suldan Z, Ward J et al (1998) A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12:1787–1800 Chiba N, Suldan Z, Freedman LP et al (2000) Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase II holoenzyme. J Biol Chem 275:10719–10722 Carvallo L, Henríquez B, Paredes R et al (2008) 1alpha, 25-Dihydroxy vitamin D3-enhanced expression of the osteocalcin gene involves increased promoter occupancy of basal transcription regulators and gradual recruitment of the 1alpha, 25-dihydroxy vitamin D3 receptor-SRC-1 coactivator complex. J Cell Physiol 214:740–749 Baudino TA, Kraichely DM, Jefcoat SC Jr et al (1998) Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 273:16434–16441 Zhang C, Dowd DR, Staal A et al (2003) Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J Biol Chem 278:35325–35336 Dunlop TW, Väisänen S, Frank C et al (2004) The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha, 25(OH)2D3 targets. J Steroid Biochem Mol Biol 89–90:257–260 Adorini L, Penna G (2009) Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 70:345–352 Cutolo M (2009) Vitamin D and autoimmune rheumatic diseases. Rheumatology 48:210–212 van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101 Liu PT, Stenger S, Li H et al (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773 Wang TT, Nestel FP, Bourdeau V et al (2004) Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173:2909–2912 Schauber J, Dorschner RA, Coda AB et al (2007) Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117:803–811 Sigmundsdottir H, Pan J, Debes GF et al (2007) DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8:285–293 Chen S, Sims GP, Chen XX et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647 Mattner F, Smiroldo S, Galbiati F et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol 30:498–508 Cippitelli M, Santoni A (1998) Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28:3017–3030 Penna G, Amuchastegui S, Cossetti C et al (2006) Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 177:8504–8511 Penna G, Amuchastegui S, Giarratana N et al (2007) 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178:145–153 Adorini L, Giarratana N, Penna G (2004) Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 16:127–134 Penna G, Adorini L (2000) 1 alpha, 25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411 Penna G, Roncari A, Amuchastegui S et al (2005) Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4 + Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 106:3490–3497 Hewison M, Freeman L, Hughes SV et al (2003) Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 170:5382–5390 Adorini L (2005) Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 233:115–124 Griffin MD, Dong X, Kumar R (2007) Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch Biochem Biophys 460:218–226 Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275–306 Lemire JM, Archer DC, Beck L et al (1995) Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 125:1704S–1708S D’Ambrosio D, Cippitelli M, Cocciolo MG et al (1998) Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101:252–262 Boonstra A, Barrat FJ, Crain C et al (2001) 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974–4980 Mahon BD, Wittke A, Weaver V et al (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89:922–932 Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13:139–145 Gregori S, Giarratana N, Smiroldo S et al (2002) A 1alpha, 25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367–1374 Gregori S, Casorati M, Amuchastegui S et al (2001) Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167:1945–1953 Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949 Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95:471–478 Antico A (2008) Autoimmune gastritis. It J Lab Med 4:125–133 De Block CE, De Leeuw IH, Van Gaal LF (2008) Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 93:363–371 Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373 Kairisto V, Poola A (1995) Software for illustrative presentation of basic clinical characteristics of laboratory tests—GraphROC for Windows. Scand J Clin Lab Invest 222:43–60 Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080–1086